• Zacks recently upgraded The Cooper Companies to a Rank #2 (Buy), reflecting analysts’ raised earnings estimates and a stronger near-term outlook for the contact lens and medical device group.
• This upgrade, alongside valuation metrics that compare favorably with peer Merit Medical, highlights how Cooper Companies’ earnings profile is drawing increased attention from value-focused investors.
• We’ll now examine how this improved earnings outlook and analyst upgrade may reshape Cooper Companies’ existing investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Cooper Companies Investment Narrative Recap

To own Cooper Companies, you need to believe its contact lens and women’s health franchises can translate steady revenue growth into improving profitability, despite recent earnings pressure. The Zacks Rank upgrade reflects higher earnings estimates, but it does not remove the key near term risk that margins stay compressed if competitive pricing, MyDAY transition noise, and weakness in CooperSurgical and PARAGARD persist. The most important catalyst in the short run remains whether the company can convert its premium lens momentum into clearer earnings traction.

Against this backdrop, the ongoing share repurchase program is particularly relevant. Cooper has bought back over 10.1 million shares for about US$1,140.4 million since 2011, and another US$13.17 million in the latest quarter. For a business balancing modest revenue guidance with a Zacks earnings upgrade, that consistent capital return matters because it can support per share results even when profit growth is patchy, and it ties directly into how investors think about the payoff from a stronger earnings outlook.

Yet, while the Zacks upgrade is encouraging, investors should be aware that ongoing pricing pressure in Asia Pacific and the uneven recovery in fertility and PARAGARD could still...

Cooper Companies' narrative projects $4.9 billion revenue and $817.1 million earnings by 2029. This requires 5.1% yearly revenue growth and an earnings increase of about $581 million from $235.8 million today.

Uncover how Cooper Companies' forecasts yield a $80.57 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a far tougher picture, even before this upgrade, with revenue only reaching about US$4.9 billion and earnings US$841.2 million by 2029, so you should know their concerns about cost savings being recycled into higher expenses before deciding which narrative fits your view.

Explore 5 other fair value estimates on Cooper Companies - why the stock might be worth 41% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cooper Companies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Cooper Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cooper Companies' overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.